Fortis Healthcare Limited (NSE:FORTIS)
India flag India · Delayed Price · Currency is INR
949.00
-7.90 (-0.83%)
May 7, 2026, 3:29 PM IST

Fortis Healthcare Earnings Call Transcripts

Fiscal Year 2026

  • Q3 25/26

    Q3 FY26 saw 17.5% revenue growth and margin expansion, with strong hospital and diagnostics performance. Expansion included 750 new beds and key acquisitions, while digital and specialized services drove higher ARPOB and profitability. Leverage remains comfortable for future growth.

  • Q2 25/26

    Q2 FY26 saw 17.3% revenue growth and 28% EBITDA increase, with strong hospital and diagnostics performance. Occupancy and margins improved, major acquisitions and expansions were completed, and guidance for continued growth and margin expansion was reiterated.

  • Q1 25/26

    Q1 FY2026 saw 16.6% revenue growth and 43.2% EBITDA increase, driven by hospital and diagnostics expansion, improved specialty mix, and digital initiatives. Margin guidance remains at 22–23%, with strong brownfield ramp-up and new O&M agreements supporting future growth.

Fiscal Year 2025

  • Q4 24/25

    FY25 saw 12.9% revenue growth, 25.3% EBITDA growth, and margin expansion, led by hospitals. Strategic acquisitions, digital growth, and bed additions support a positive FY26 outlook with further margin and revenue gains expected.

  • Q3 24/25

    Q3 FY25 delivered 14.8% revenue growth and 32% higher EBITDA, driven by strong hospital performance and specialty mix. Diagnostic margins improved, with rebranding costs set to taper off. CapEx and expansion remain focused on brownfield projects, with margin and growth guidance maintained.

  • Q2 24/25

    Q2 FY25 saw 12.3% revenue growth and a 31.9% rise in operating EBITDA, with hospital margins exceeding 21% and diagnostics margins improving to 21.5%. Brownfield expansions and digital initiatives are driving growth, while the Agilus stake acquisition and ongoing legal matters are key developments.

  • Q1 24/25

    Q1 FY25 delivered 12.2% revenue growth and 25.5% EBITDA growth, led by hospitals, while diagnostics remained flat due to rebranding costs. Brownfield expansions, digital growth, and a planned Agilus stake buyout support a positive outlook, with hospital margins on track for 20%+ this year.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Powered by